Cancer-Associated Fibroblast Lactate Promotes Oxaliplatin Resistance via ANTXR1 Lactylation in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains one of the most prevalent and deadly malignancies worldwide, accounting for roughly 9.3% of all cancer deaths (paper). Oxaliplatin-based chemotherapy is a cornerstone in the treatment of both metastatic and non-metastatic CRC. However, resistance to oxaliplatin poses a significant clinical challenge, as up to 40% of patients with advanced CRC develop either primary or acquired resistance, markedly diminishing therapeutic efficacy (paper). The mechanistic underpinnings of this resistance remain incompletely understood. Increasing evidence implicates the tumor microenvironment—particularly cancer-associated fibroblasts (CAFs)—in modulating cancer cell behavior, including drug resistance. CAFs are known to contribute to tumor progression through paracrine signaling, metabolic reprogramming, and extracellular matrix remodeling. The present study sought to determine how CAF-derived metabolic products, specifically lactate, influence CRC cell response to oxaliplatin, focusing on cancer stemness and the molecular mediators involved.

Key Innovation from the Reference Study

The pivotal innovation of this research lies in the identification of a metabolic communication axis between CAFs and CRC cells that drives chemoresistance. The authors demonstrate that lactate secreted by glycolytically active CAFs induces both histone lactylation and direct lactylation of ANTXR1 (Anthrax Toxin Receptor 1) at lysine 453. This dual modification upregulates ANTXR1 expression and stability, activating downstream RhoC/ROCK1/SMAD5 signaling. This pathway enhances cancer stem cell (CSC) properties and triggers resistance to oxaliplatin. Notably, inhibition of lactate shuttling or genetic/pharmacologic targeting of the identified axis sensitizes CRC cells to oxaliplatin, both in vitro and in xenograft models (paper).

Methods and Experimental Design Insights

The study utilized a multi-tiered experimental approach to dissect the metabolic crosstalk between CAFs and CRC cells:

• CAF Isolation and Characterization: CAFs were isolated from primary CRC tissue and assessed for glycolytic activity via lactate production assays.
• Co-culture and Conditioned Media Models: CRC cells were exposed to CAF-conditioned media or directly co-cultured to model the tumor microenvironment.
• Gene Expression and Protein Modification Analysis: The study employed RT-qPCR, Western blotting, and immunoprecipitation to quantify ANTXR1 expression and detect lactylation at specific lysine residues.
• Chromatin Immunoprecipitation (ChIP): To assess histone lactylation and its impact on ANTXR1 transcription, ChIP assays were performed.
• Functional Assays: CSC properties were evaluated through sphere formation assays, flow cytometry for stem cell markers (e.g., LGR5, CD44), and in vivo tumorigenicity in xenograft models.
• Pharmacological and Genetic Interventions: Inhibitors of lactate transport and genetic knockdown of ANTXR1 or pathway components assessed pathway specificity and therapeutic potential.

Protocol Parameters

• CAF-CRC co-culture duration | 48–72 hours | modeling tumor-stroma interaction | Ensures sufficient lactate accumulation and signaling transfer | paper
• Oxaliplatin concentration | 2–10 μM | in vitro chemoresistance assay | Reflects clinically relevant plasma levels for CRC | paper
• Sphere formation period | 7–14 days | CSC enrichment evaluation | Allows quantification of self-renewal and stemness | paper
• DNase I (RNase-free) use for RNA prep | 1 U/μg RNA, 15–30 min at 37°C | DNA removal for RNA extraction | Minimizes genomic DNA contamination in RT-qPCR | workflow_recommendation

Core Findings and Why They Matter

The authors present robust evidence that metabolic reprogramming in CAFs—specifically heightened glycolysis and lactate secretion—directly induces chemoresistance in CRC cells through a novel epigenetic and posttranslational mechanism (paper). Key findings include:

• Lactate Transfer: CAF-derived lactate is taken up by CRC cells, driving both histone lactylation (altering gene transcription) and direct lactylation of ANTXR1 at K453.
• ANTXR1 Upregulation and Stabilization: Lactylation increases ANTXR1 transcription and protein stability, correlating with poor prognosis and increased oxaliplatin resistance.
• CSC Promotion: Enhanced ANTXR1 activity boosts the RhoC/ROCK1/SMAD5 signaling pathway, promoting stemness features such as self-renewal and therapy resistance.
• Therapeutic Reversal: Disruption of lactate shuttling or ANTXR1 function resensitizes CRC cells to oxaliplatin in both cell culture and xenograft models, implying translational potential for combination therapies.

This study underscores the importance of metabolic and stromal contributions to chemoresistance, highlighting ANTXR1 lactylation as a key mediator and actionable target.

Comparison with Existing Internal Articles

Recent internal resources have explored the challenges of DNA contamination and the role of robust nucleic acid preparation in tumor microenvironment models:

• The article "DNase I (RNase-free): Precision DNA Digestion Empowering ..." emphasizes the significance of precise DNA removal for RNA extraction and RT-PCR, particularly in complex cancer models where stromal-epithelial interactions (such as those described in the present study) can complicate nucleic acid isolation.
• "Redefining DNA Digestion..." specifically discusses the application of ribonuclease-free DNase I in organoid-stroma co-culture, paralleling the CAF-CRC systems used in the reference study, and highlights the need for high-fidelity DNA removal to ensure reliable gene expression quantification.
• For practical laboratory workflows, "Practical Laboratory Scenarios with DNase I (RNase-free):..." offers guidance on maintaining RNA integrity and minimizing DNA contamination, which is essential for accurate assessment of transcriptional regulation, such as histone lactylation effects on ANTXR1.

While these internal works focus on methodological rigor and technical troubleshooting in molecular assays, the reference study bridges these considerations with cutting-edge biological insight, reinforcing the need for meticulous sample preparation in tumor microenvironment research.

Limitations and Transferability

The study's strengths include the integration of in vitro, in vivo, and molecular mechanistic data. Nevertheless, several limitations warrant consideration:

• CAF Heterogeneity: The CAFs used were derived from selected patient samples, and inter-patient variability may affect the generalizability of the findings.
• Clinical Translation: While inhibition of the lactate shuttle shows promise in preclinical models, the efficacy and safety of such interventions in patients remain to be established.
• Specificity of ANTXR1 Modifications: The downstream impact of ANTXR1 lactylation may be context-dependent and needs further validation in diverse CRC backgrounds.

Nonetheless, the mechanistic insights are likely transferable to other tumor systems where stromal-epithelial metabolic crosstalk and CSC-mediated drug resistance are evident.

Research Support Resources

To facilitate reproducible results in studies involving tumor-stroma interactions and gene expression analysis, researchers can employ DNase I (RNase-free) (SKU K1088) for rigorous DNA removal during RNA extraction, RT-PCR, and in vitro transcription protocols. This ribonuclease-free DNase I ensures minimal DNA contamination, supporting accurate quantification of transcriptional changes such as those driven by histone lactylation or metabolic crosstalk (internal article). For researchers modeling complex tumor microenvironments or seeking to investigate DNA-protein interactions, APExBIO’s enzyme offers reproducible performance across workflows.